
Global Perspectives in Urothelial Carcinoma (2025) – LATAM Focus Spanish Webcast

The 2025 Global Perspectives in Urothelial Carcinoma is an educational series focused on the latest advancements in Urothelial Carcinoma (UC) designed to meet the educational needs of our global audience. The series will consists of three live webinars presented in English with a focus on three different regions (German, LATAM and Japan). Each activity will include a US based moderator and panel of local faculty to the region, including urologists and a medical oncologist . This 90- minute virtual activity will explore the evolving therapeutic options for patients with locally advanced (la) or metastatic urothelial carcinoma (mUC), discuss the value of early identification and management of adverse events associated with UC, and the importance of patient education. Local experts will discuss how AUA and local regional clinical guidelines translate into practice and the various roles played by the multidisciplinary team in the treatment advanced and metastatic urothelial carcinoma.
Presented in English, the activity is of value to the global urologic community.
This live virtual event will offer simultaneous translation in 50+ languages. Powered by an involved AI based technology Wordly, attendees will be able to access the audio and captioning translations in real time to help make the course more accessible to our colleagues around the globe.
This part of the series is presented by the AUA in partnership with the Sociedade Brasileira de Urologia (SBU) and Confederación Americana de Urología (CAU) and focuses on the latest advancements in Urothelial Carcinoma in Latin America.
ACKNOWLEDGEMENTS
Support provided by an independent educational grant from:
- Astellas and Pfizer, Inc.
Target Audience
- Urologists
Learning Objectives
After participating in this CME activity, participants will be able to:
- Identify new and emerging treatment options in the locally advanced (la)/metastatic urothelial carcinoma (mUC) setting, including combination regimens and optimal sequencing.
- Analyze mechanisms of action of novel agents in the la/mUC setting.
- Address the roles of the urologist, medical oncologist, radiation oncologist, and other clinicians in delivering holistic, multidisciplinary care to UC patients.
- Incorporate AUA and relevant local/regional clinical guidelines updates for UC treatments into practice.
- Properly manage adverse events associated with therapies for la and mUC and discuss ways to improve early identification.
- Determine appropriate management strategies to reduce the incidence of AEs to minimize morbidity, including identifying methods to leverage multidisciplinary teams and advanced practice providers to achieve these goals.
Program coming soon!
EDUCATION COUNCIL DISCLOSURE
Education Council DTL 2025_1.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup DTL 2025_1.pdf
FACULTY DISCLOSURES
| Name | Company Name | Relationship Type | End Date |
| Barragan Carrillo, Regina | Synthon | Consultant or Advisor | Current |
| Ipsen | Consultant or Advisor | Current | |
| Burger, Maximilian, Prof. Dr. | AstraZeneca GmbH | Meeting Participant or Lecturer | Current |
| Bayer Vital GmbH | Meeting Participant or Lecturer | Current | |
| Ferring Arzneimittel GmbH | Meeting Participant or Lecturer | Current | |
| Janssen-Cilag GmbH | Meeting Participant or Lecturer | Current | |
| MSD Sharp & Dohme GmbH | Meeting Participant or Lecturer | Current | |
| Pfizer PHarma GmbH | Meeting Participant or Lecturer | Current | |
| Photocure ASA - The Bladder Company | Meeting Participant or Lecturer | Current | |
| Accord Health Care GmbH | Scientific Study or Trial | Current | |
| Medac GmbH | Meeting Participant or Lecturer | Current | |
| Birstol-Myers Squibb GmbH & Co KG | Meeting Participant or Lecturer | Current | |
| Astellas Pharma GmbH | Meeting Participant or Lecturer | Current | |
| Chang, Sam S. | Pfizer | Consultant or Advisor | Current |
| Urogen | Consultant or Advisor | Current | |
| Prokarium | Consultant or Advisor | Current | |
| Merck | Consultant or Advisor | Current | |
| Pacific Edge | Consultant or Advisor | Current | |
| Nonagen | Consultant or Advisor | Current | |
| Astra Zeneca | Consultant or Advisor | Current | |
| Ferring | Scientific Study or Trial | Current | |
| LynxDx | Consultant or Advisor | Current | |
| Engene | Consultant or Advisor | Current | |
| Johnson and Johnson | Consultant or Advisor | Current | |
| Chipollini, Juan | No relevant financial relationships to disclose | ||
| Eto, Masatoshi | Pfizer | Meeting Participant or Lecturer | Current |
| Novartis | Meeting Participant or Lecturer | Current | |
| Ono Pharmaceutical | Meeting Participant or Lecturer | Current | |
| Bristol-Myers Squibb | Meeting Participant or Lecturer | Current | |
| Bayer | Meeting Participant or Lecturer | Current | |
| Janssen | Meeting Participant or Lecturer | Current | |
| MSD | Meeting Participant or Lecturer | Current | |
| Chugai | Meeting Participant or Lecturer | Current | |
| Merck | Meeting Participant or Lecturer | Current | |
| AstraZeneca | Meeting Participant or Lecturer | Current | |
| Eisai | Meeting Participant or Lecturer | Current | |
| Astellas Pharma | Meeting Participant or Lecturer | Current | |
| Fernandez, Mario Ignacio | No relevant financial relationships to disclose | ||
| Inokuchi, Junichi | Astellas Pharma Inc. | Meeting Participant or Lecturer | Current |
| Merck & Co., Inc. | Meeting Participant or Lecturer | Current | |
| ONO Pharmaceutical | Meeting Participant or Lecturer | Current | |
| Kitamura, Hiroshi | Astellas | Scientific Study or Trial | Current |
| Pfizer | Meeting Participant or Lecturer | Current | |
| Astra Zeneca | Meeting Participant or Lecturer | Current | |
| Janssen | Meeting Participant or Lecturer | Current | |
| Sanofi | Meeting Participant or Lecturer | Current | |
| Bristol-Myers Squibb | Meeting Participant or Lecturer | Current | |
| MSD | Meeting Participant or Lecturer | Current | |
| Kissei | Consultant or Advisor | Current | |
| Merck Biopharma | Meeting Participant or Lecturer | Current | |
| Nippon Shinyaku | Meeting Participant or Lecturer | Current | |
| Matin, Surena Fazeli | Merck | Consultant or Advisor | Current |
| Ferring Pharmaceuticals | Scientific Study or Trial | Current | |
| Nogueira, Lucas Mendes | Bayer | Consultant or Advisor | Current |
| Astellas Pharma | Meeting Participant or Lecturer | Current | |
| Janssen | Meeting Participant or Lecturer | Current | |
| MSD | Consultant or Advisor | Current | |
| Reis, Rodolfo Borges | Astra Zeneca | Meeting Participant or Lecturer | Current |
| Thomas, Christian | Astellas | Meeting Participant or Lecturer | Current |
| Johnson and Johnson | Consultant or Advisor | Current | |
| Bayer | Meeting Participant or Lecturer | Current | |
| von Amsberg, Gunhild | Astrazeneca | Consultant or Advisor | Current |
| Yajima, Shugo | No relevant financial relationships to disclose | ||
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 1.50 hours
Release Date: October, 2025
Expiration Date: October, 2026
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
AUA ACCREDITATION INFORMATION
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
DISCLAIMER:
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
REPRODUCTION PERMISSION:
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation

Facebook
X
LinkedIn
Forward